Enzyme producer Verenium managed to survive the 2008 financial crisis and cellulosic ethanol commercialization delays by remaking itself and engaging in multiple well-timed asset and segment sales. While the company's balance sheet is now stronger than it has been in several years, it will now need to see strong revenue growth resulting from its new enzyme products if its share price is to recover even a fraction of the losses that it experienced in 2007 and 2008. This is a very speculative stock.
While 2007 and 2008 witnessed the bursting of several bubbles, one of the largest in the cellulosic biofuels sector was the rapid fall of Verenium Corporation (VRNM). Formed in Q2 2007...
Only subscribers can access this article, which is part of the PRO research library covering 3,594 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: